Introducing cholera vaccination in Asia, Africa and Haiti: A meeting report
Introducing cholera vaccination in Asia, Africa and Haiti: A meeting report
复制标题
DOI：
10.1016/j.vaccine.2014.11.031
复制
发表时间：
2015-01-15
期刊：
影响因子：
5.5
通讯作者：
Sack, David A.
中科院分区：
文献类型：
--
作者：
Hall, Robert H.;Sack, David A.
口服霍乱疫苗（OCV）已越来越多地作为一种额外的工具来干预地方性和流行性霍乱。2013年，印度、孟加拉国、越南、几内亚、海地和泰国报告了OCV在9个不同现场环境下的短期和长期现场经验。这些项目的主要研究人员在由大卫博士主持的研讨会上介绍了他们的发现。作者声明：Robert H. 2013年11月7日，在曼谷举行的肠道疾病疫苗（VED）会议上的大厅。研讨会的目的是描述每个环境和项目的独特性，分享实施霍乱疫苗接种的实地经验，讨论结果，并确定更广泛使用OCV的限制因素。VED提供了一个论坛，超过200名与会者参与了霍乱领域这一令人兴奋和潜在决定性的新发展。
Orally-administered cholera vaccine (OCV) has been increasingly examined as an additional tool to intervene against endemic and epidemic cholera. In 2013, short- and long-term field experience with OCV under nine distinctive field settings was reported from India, Bangladesh, Vietnam, Guinea, Haiti, and Thailand. Lead investigators from each of these projects presented their findings at a symposium chaired by Drs. David A. Sack and Robert H. Hall at the Vaccines for Enteric Diseases (VED) Conference in Bangkok on November 7, 2013. The objective of the symposium was to describe the unique features of each setting and project, share field experience of implementing cholera vaccination, discuss results, and identify constraints to the wider use of OCV. The VED provided a forum where >200 attendees engaged with this exciting and potentially decisive new development in the cholera field.